The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols
Abstract
Extrapolation of animal data to assess pharmacokinetic parameters in humans is an important tool in drug development. Allometric scaling has many proponents, and many different approaches and techniques have been proposed to optimise the prediction of pharmacokinetic parameters from animals to humans. The allometric approach is based on the power function Y = aWb, where the bodyweight of the species is plotted against the pharmacokinetic parameter of interest on a log-log scale. Clearance, volume of distribution and elimination half-life are the 3 most frequently extrapolated pharmacokinetic parameters. Clearance is not predicted very well (error between predicted and observed clearance > 30%) using the basic allometric equation in most cases. Thus, several other approaches have been proposed. An early approach was the concept of neoteny, where the clearance is predicted on the basis of species bodyweight and maximum life-span potential. A second approach uses a 2-term power equation based on brain and body weight to predict the intrinsic clearance of drugs that are primarily eliminated by phase I oxidative metabolism. Most recently, the use of the product of brain weight and clearance has been proposed. A literature review reveals different degrees of success of improved prediction with the different methods for various drugs. In a comparative study, the determining factor in selecting a method for prediction of clearance was found to be the value of the exponent. Integration of in vitro data into in vivo clearance to improve the predictive performance of clearance has also been suggested. Although there are proponents of using body surface area instead of bodyweight, no advantage has been noted in this approach. It has also been noted that the unbound clearance of a drug cannot be predicted any better than the total body clearance (CL). In general, there is a good correlation between bodyweight and volume of the central compartment (Vc); hence, Vc does not face the same complications as CL. The relationship between elimination half-life (t 1/2 beta) and bodyweight across species results in poor correlation, most probably because of the hybrid nature of this parameter. When a reasonable prediction of CL and Vc is made, t 1/2 beta may be predicted from the equation t 1/2 beta = 0.693 Vc/CL.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
For drugs excreted renally or via extensive metabolism, CLu could not be predicted any better than total CL.
“Furthermore, Mahmood [6] has compared total CL and CLu and found that for drugs excreted renally or via extensive metabolism, CLu could not be predicted any better than total CL.”
From Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling (2019) · cites this paper as [6]
Cites
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257 · see citing works
Self-citationMahmood, I., & Balian, J. D. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00339-6 · Cited by 72 · see citing works
Self-citationChiou, W. L., & Hsu, F.-H. (1988) · Pharmaceutical Research · doi:10.1023/a:1015935206569 · Cited by 28 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Pharmacokinetic/Pharmacodynamic Modeling in Drug Development
Sheiner, L. B., & Steimer, J.-L. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.67 · Cited by 351 · see citing works
Translating dosages from animal models to human clinical trials—revisiting body surface area scaling
Blanchard, O. L., & Smoliga, J. M. (2015) · The FASEB Journal · doi:10.1096/fj.14-269043 · Cited by 183 · see citing works
Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Liric Rajlic, I., & Obach, R. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440282 · Cited by 106 · see citing works
Shiran, M. R., Proctor, N. J., Howgate, E. M., Rowland-Yeo, K., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600761662 · Cited by 89 · see citing works
Choi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 76 · see citing works
“In their studies, they compared the CL value of antiepileptic drugs using four different allometric equations: a simple AS in Equation (74), the product of CL and MPL in Equation (75), the Boxenbaum’s two-term power function in Equation (77), and the product of CL and BW in Equation (76), a novel equation developed by…”
BackgroundInfluentialSmoliga, J. M., & Blanchard, O. L. (2017) · Functional Foods in Health and Disease · doi:10.31989/ffhd.v7i5.345 · Cited by 11 · see citing works
- Authors
- Mahmood, I., & Balian, J. D.
- Affiliations
- United States Food and Drug Administration (US)
- Corresponding author
- Mahmood, Iftekhar
- ORCID
- Mahmood, Iftekhar
- Venue
- Clinical Pharmacokinetics
- Published
- 1999
- Volume
- 36
- Issue
- 1
- Pages
- 1-11
- ISSN
- 0312-5963 (ISSN-L)
- OpenAlex
- W1998519118
- Cited by
- 112
- References
- 3
- Citations by year
- 2026: 4 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 2 · 2017: 5 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 8 · 2012: 3
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacokinetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- allometric scaling, interspecies extrapolation, pharmacokinetic parameters, clearance prediction, volume of distribution, elimination half-life, neoteny, brain weight, intrinsic clearance, phase I metabolism, body weight, body surface area, in vitro-in vivo correlation
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Pharmacokinetics, Species Specificity, Clinical Trials, Phase I as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review